Landon Capital

Landon capital

Capital Market News, Capital Markets Now

CETY

2.32 USD

+ 116.82%
LIXTW

0.0211 USD

+ 111.00%
BCGWW

0.12 USD

+ 104.08%
DSYWW

0.0384 USD

+ 73.76%
NRXPW

0.1043 USD

+ 59.97%
REVBW

0.0108 USD

+ 54.29%
RUBI

0.2355 USD

+ 54.22%
CLNNW

0.007 USD

+ 52.17%
KZIA

12.79 USD

+ 51.36%
NIVFW

0.0246 USD

+ 49.09%
RVPHW

0.0116 USD

+ 45.00%
IVDAW

0.1469 USD

+ 43.04%
MTEKW

0.19 USD

+ 42.86%
KSS

22.41 USD

+ 42.47%
FSHPR

0.17 USD

+ 41.55%
PAVS

0.8209 USD

+ 41.34%
OPENZ

0.9101 USD

+ 39.89%
SYM

77.29 USD

+ 39.36%
RVMDW

0.9 USD

+ 38.48%
ANF

90.27 USD

+ 37.59%

Top Gainer

Latest News

FDA approves AstraZeneca’s Imfinzi for early-stage stomach and GEJ cancers AstraZeneca’s (OTC: AZNCF) cancer drug Imfinzi (durvalumab) has been approved in the United States as a treatment for adults with certain types of stomach and gastroesophageal junction (GEJ) cancers that can be surgically removed. The drug is used along with standard chemotherapy before and after surgery, and then by itself …

A deal is a deal, Veralto (NYSE: VLTO) to acquire In-Situ for $435 million Veralto Corporation (NYSE: VLTO) announced it has entered into a definitive agreement to acquire In-Situ, a Colorado-based environmental water measurement company, for $435 million, subject to customary closing adjustments. The purchase price, after considering estimated tax benefits, is approximately $422 million. The transaction is expected to …